Mostrando 2 resultados de: 2
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusManufacturing process development for an epidermal growth factor-based cancer vaccine
ArticleAbstract: The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapyPalabras claves:Autores:Albisa A., Calvo L., Chico E., Cuevas A., Garcia A.T., García Verdecia B., González G., Portillo A., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopus